Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis

In-depth characterization of CD24 high CD38 high transitional human B cells reveals different regulatory profiles

(2016) Quentin Simon et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

NFκB1 is essential to prevent the development of multiorgan autoimmunity by limiting IL-6 production in follicular B cells

(2016) Elisha de Valle et al.   JOURNAL OF EXPERIMENTAL MEDICINE

BSR and BHPR guideline for the treatment of systemic sclerosis

(2016) Christopher P. Denton et al.   RHEUMATOLOGY

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

(2014) Suzana Jordan et al.   ANNALS OF THE RHEUMATIC DISEASES

2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

(2013) Frank van den Hoogen et al.   ARTHRITIS AND RHEUMATISM

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

(2012) Saba Alzabin et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

(2012) Tom A. Barr et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer

(2011) Markus F. Neurath et al.   CYTOKINE & GROWTH FACTOR REVIEWS

CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients

(2010) Paul A. Blair et al.   IMMUNITY

Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo

(2010) Dimitrios Daoussis et al.   RHEUMATOLOGY INTERNATIONAL

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis

(2009) Robert Lafyatis et al.   ARTHRITIS AND RHEUMATISM

Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells

(2009) S. Suryani et al.   BLOOD

Killer B lymphocytes: the evidence and the potential

(2009) Steven K. Lundy   INFLAMMATION RESEARCH

The Development and Function of Regulatory B Cells Expressing IL-10 (B10 Cells) Requires Antigen Receptor Diversity and TLR Signals

(2009) K. Yanaba et al.   JOURNAL OF IMMUNOLOGY

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

(2009) Dimitrios Daoussis et al.   RHEUMATOLOGY

CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma

(2008) Ayumi Yoshizaki et al.   AMERICAN JOURNAL OF PATHOLOGY

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

(2008) V Smith et al.   ANNALS OF THE RHEUMATIC DISEASES

Sites and Stages of Autoreactive B Cell Activation and Regulation

(2008) Mark J. Shlomchik   IMMUNITY

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

(2008) Satoshi Serada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA